Laboratory Corporation of America Holdings (LH) , or Labcorp, reported adjusted earnings per share (EPS) of $3.94 in the second quarter of 2024, up 15.2% from the year-ago quarter's figure. The adjusted figure excludes the impact of certain amortization expenses and restructuring charges, among others. The bottom line also beat the Zacks Consensus Estimate by 4.2%. On a GAAP basis, EPS in the second quarter was $2.43, up 14.6% from last year's comparable period. Revenues Revenues in the quarter under review ...

财务数据和关键指标变化 - 第二季度收入为32亿美元,同比增长6.2% [10] - 调整后每股收益为3.94美元,同比增长15% [27] - 来自持续经营的自由现金流为4.33亿美元 [27] 各条业务线数据和关键指标变化 - 诊断业务收入增长7.9%,其中有机增长4.7% [29] - 生物医药实验室服务收入增长1.1%,其中有机增长1.2% [31] - 诊断业务调整后营业利润率为17.5%,与去年持平 [30] - 生物医药实验室服务调整后营业利润率为15.2%,同比上升 [32] 各个市场数据和关键指标变化 - 公司继续保持作为医疗系统和地区性实验室首选合作伙伴的领导地位 [13][14] - 公司宣布收购Invitae,预计未来将带来10%以上的收入增长 [15][16] 公司战略和发展方向及行业竞争 - 公司专注于科技创新,推出多项新的诊断测试和服务 [18][19][20][21] - 公司通过收购和战略合作不断扩大业务规模和服务范围 [13][14][15] - 公司在精准医疗和基因检测领域持续保持领先地位 [18] 管理层对经营环境和未来前景的评论 - 管理层对公司未来保持信心,预计诊断和生物医药实验室服务业务将保持强劲增长 [9][12] - 管理层认为Invitae收购将为公司带来重要的战略和财务价值 [15][16][17] 其他重要信息 - 公司宣布增加10亿美元的股票回购计划 [28] - 公司预计2024年收入增长6.4%-7.5%,调整后每股收益14.30-14.90美元 [33][34][37] 问答环节重要的提问和回答 问题1 **Michael Cherny 提问** 询问早期开发业务订单和取消情况,以及对未来业务恢复的预期 [39][40] **Adam Schechter 回答** 解释早期开发业务订单和取消情况改善,预计下半年业务将恢复增长 [41][42][43] 问题2 **Andrew Brackmann 提问** 询问Invitae收购对客户和业务的影响 [45] **Adam Schechter 回答** 表示Invitae的产品线和技术与公司战略高度契合,有望为客户带来更多增值服务 [46][47][48] 问题3 **Eric Coldwell 提问** 询问早期开发业务的收入预期和趋势 [53][54][55][56] **Glenn Eisenberg 回答** 解释早期开发业务收入预期,预计下半年将逐步恢复增长 [54][55][56]

Thursday, Laboratory Corp A reported second-quarter 2024 adjusted EPS of $3.94, up from $3.42 a year ago, beating the consensus of $3.78. Sales increased 6.2% year-over-year to $3.22 billion, beating the consensus of $3.19 billion. The increase was due to organic revenue of 3.8%, acquisitions, and net of divestitures of 2.5%, partially offset by foreign currency translation of (0.1%). The 3.8% increase in organic revenue was driven by a 4.5% increase in the company's organic Base Business, partially offset ...

Laboratory Corporation of America Holdings (LH) , or Labcorp, reported adjusted earnings per share (EPS) of $3.94 in the second quarter of 2024, up 15.2% from the year-ago quarter's figure. The adjusted figure excludes the impact of certain amortization expenses and restructuring charges, among others. The bottom line also beat the Zacks Consensus Estimate by 4.2%. On a GAAP basis, EPS in the second quarter was $2.43, up 14.6% from last year's comparable period. Revenues Revenues in the quarter under review ...

For the quarter ended June 2024, Labcorp (LH) reported revenue of $3.22 billion, up 6.2% over the same period last year. EPS came in at $3.94, compared to $3.42 in the year-ago quarter. The reported revenue compares to the Zacks Consensus Estimate of $3.2 billion, representing a surprise of +0.78%. The company delivered an EPS surprise of +4.23%, with the consensus EPS estimate being $3.78. While investors scrutinize revenue and earnings changes year-over-year and how they compare with Wall Street expectati ...

Labcorp (LH) came out with quarterly earnings of $3.94 per share, beating the Zacks Consensus Estimate of $3.78 per share. This compares to earnings of $3.42 per share a year ago. These figures are adjusted for nonrecurring items. This quarterly report represents an earnings surprise of 4.23%. A quarter ago, it was expected that this medical laboratory operator would post earnings of $3.46 per share when it actually produced earnings of $3.68, delivering a surprise of 6.36%. Over the last four quarters, the ...

财务业绩 - 2024年第二季度收入为32.2亿美元，同比增长6.2%[14] - 2024年第二季度调整后每股收益为3.94美元，同比增长15.2%[16] - 2024年全年收入增长预期为6.4%至7.5%，其中Invitae公司的影响约为1.0%[32] - 2024年全年调整后每股收益预期为14.30美元至14.90美元，其中Invitae公司的摊薄影响约为0.40美元[33] - 2024年全年自由现金流预期为8.5亿美元至10亿美元，其中Invitae公司的现金使用约为1.5亿美元[34] - 2024年第二季度收入为32.21亿美元，同比增长6.2%[44] - 2024年上半年收入为63.98亿美元，同比增长5.4%[44] - 2024年第二季度净利润为2.05亿美元，同比增长14.5%[45] - 2024年上半年净利润为4.33亿美元，同比增长19.3%[45] - 公司2024年第二季度和上半年收入分别为32.21亿美元和63.98亿美元，同比增长6.2%和5.4%[55] - 诊断实验室业务2024年第二季度和上半年收入分别为25.25亿美元和50.05亿美元，同比增长7.9%和6.0%[52] - 生物制药实验室服务业务2024年第二季度和上半年收入分别为7.07亿美元和14.18亿美元，同比增长1.1%和4.2%[53] - 2024年第二季度和上半年调整后营业利润分别为4.80亿美元和9.33亿美元，同比增长7.0%和4.1%[56] - 2024年第二季度和上半年调整后营业利润率分别为14.9%和14.6%[56] - 2024年第二季度和上半年经调整每股收益分别为3.94美元和7.62美元，同比增长15.2%和10.7%[61] - 2024年第二季度和上半年经营活动产生的现金流分别为5.61亿美元和5.31亿美元，同比增长59.6%和12.3%[50] - 2024年第二季度和上半年资本支出分别为1.28亿美元和2.62亿美元，同比增长24.1%和44.3%[50] - 2024年第二季度和上半年进行了3.39亿美元和29.31亿美元的企业收购[50] - 2024年第二季度和上半年支付了1.00亿美元和1.23亿美元的股息[50] 业务发展 - 公司获得FDA批准用于血友病B基因疗法的伴随诊断[8] - 公司推出首个三个月孕期子痫前期筛查检测[9] - 公司扩大精准肿瘤组合服务,包括在日内瓦和上海提供Labcorp® Tissue Complete和添加OmniSeq INSIGHT液体活检基因组分析服务[10] - 公司推出Labcorp Global Trial Connect,提供中央实验室解决方案以加快临床试验[11] - 公司扩大Labcorp OnDemand服务,新增多项检测[12] 财务状况 - 2024年6月30日现金及现金等价物余额为2.65亿美元[49] - 2024年6月30日应收账款净额为20.89亿美元[49] - 2024年6月30日商誉净额为62.20亿美元[49] - 2024年6月30日无形资产净额为33.32亿美元[49] - 2024年6月30日总资产为167.12亿美元[49] - 2024年6月30日总负债为86.92亿美元[49] 重组和整合 - 公司进行了业务重组和精简冗余职位及设施,涉及LaunchPad计划、Fortrea公司的分拆以及收购或出售业务[1] - 公司发生了与收购和处置相关的成本,包括尽职调查、法律和咨询费用、保留奖金、延迟合同或许可转让的影响以及其他整合或处置相关活动[1] - 公司发生了与LaunchPad计划实施相关的非资本化成本,包括系统整合、流程整合以及各种业务流程改进举措的咨询费用[1] - 公司为Fortrea的分拆和剩余Labcorp业务的重组发生了各种成本[1] - 公司对某些固定资产和资本化软件成本进行了减值,因为这些资产已不再为业务所用[1] - 公司从Fortrea收取了过渡服务费,用于提供行政和IT系统支持,但提供这些服务的成本计入了营业收入[1] - 公司对Fortrea分拆后的临床开发和商业化服务业务进行了调整[1] 其他 - 公司对一些投资公司或基金进行了投资,并记录了相关的收益和损失[1] - 公司出售了Beacon Laboratory Benefits Solutions业务并记录了收益[1] - 公司因结算美国养老金计划的某些义务而产生了费用[1]

Updates Full-Year Guidance Results from Continuing Operations for second quarter 2024 versus last year: Revenue: $3.22 billion versus $3.03 billion Diluted EPS: $2.43 versus $1.74 Adjusted EPS: $3.94 versus $3.42 Free Cash Flow: $432.9 million versus $58.2 million Updated Full-Year 2024 Guidance: Revenue range of 6.4% to 7.5%, includes Invitae impact of ~1.0% Adjusted EPS range of $14.30 to $14.90, includes Invitae dilution of ~$0.40 Free Cash Flow of $0.85 billion to $1.00 billion, includes Invitae cash us ...

BURLINGTON, N.C., and FREMONT, Calif., July 29, 2024 /PRNewswire/ -- Labcorp (NYSE: LH), a global leader of innovative and comprehensive laboratory services, today announced an expanded collaboration with Ultima Genomics to utilize its UG 100TM sequencing solution and ppmSeqTM technology to explore new whole genome sequencing (WGS) clinical applications, including molecular residual disease (MRD) in patients with early-stage solid tumor cancers. Labcorp recently introduced Labcorp® Plasma Detect™, the first ...

Laboratory Corporation of America Holdings (LH) , or Labcorp, is slated to report second-quarter 2024 results on Aug 1 before market open. The Zacks Consensus Estimate for Labcorp's second-quarter 2024 revenues is pegged at $3.20 billion. This suggests a 5.4% rise from the year-ago reported figure. Estimates for Labcorp's Q2 earnings have remained unchanged at $3.78 per share in the past 30 days. In the second quarter of 2024, both Diagnostic Laboratories (Dx) and Biopharma Laboratory Services ("BLS") segme ...